Addex Financial Statements From 2010 to 2025

ADXN Stock  USD 8.83  0.17  1.89%   
Addex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Addex Therapeutics' valuation are provided below:
Gross Profit
-519.1 K
Profit Margin
35.2174
Market Capitalization
9.4 M
Enterprise Value Revenue
28.1504
Revenue
246.2 K
We have found one hundred twenty available fundamental signals for Addex Therapeutics, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Addex Therapeutics' prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 17th of July 2025, Market Cap is likely to drop to about 5.3 M. In addition to that, Enterprise Value is likely to drop to about 2.2 M

Addex Therapeutics Total Revenue

383,897

Check Addex Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Addex Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 247.1 K, Interest Expense of 3.4 K or Total Revenue of 383.9 K, as well as many indicators such as Price To Sales Ratio of 13.0, Dividend Yield of 0.0 or PTB Ratio of 0.55. Addex financial statements analysis is a perfect complement when working with Addex Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Addex Stock
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.

Addex Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets10.1 M10.7 M17.6 M
Slightly volatile
Short and Long Term Debt Total39.9 K42 K433 K
Slightly volatile
Other Current Liabilities492.9 K518.8 K1.3 M
Pretty Stable
Total Current Liabilities762 K802.1 KM
Slightly volatile
Total Stockholder Equity9.2 M9.7 M13.9 M
Slightly volatile
Property Plant And Equipment Net40.6 K42.7 K785.9 K
Slightly volatile
Current Deferred Revenue412.9 K270.2 K289.9 K
Slightly volatile
Accounts Payable240.6 K253.3 K1.4 M
Slightly volatile
Cash3.2 M3.3 M14.6 M
Slightly volatile
Non Current Assets Total7.5 M7.1 M2.2 M
Very volatile
Non Currrent Assets Other6.7 K7.1 K527.5 K
Slightly volatile
Cash And Short Term Investments3.2 M3.3 M14.6 M
Slightly volatile
Common Stock Total Equity39.7 M37.8 M21.6 M
Slightly volatile
Common Stock Shares Outstanding858.5 K817.6 K257.8 K
Slightly volatile
Liabilities And Stockholders Equity10.1 M10.7 M17.6 M
Slightly volatile
Other Current Assets168.7 K177.6 K504.1 K
Slightly volatile
Other Stockholder Equity289.3 M330.1 M270.3 M
Slightly volatile
Total Liabilities951 KM3.7 M
Slightly volatile
Property Plant And Equipment Gross186.6 K196.4 K1.6 M
Very volatile
Total Current Assets3.4 M3.5 M15.4 M
Slightly volatile
Short Term Debt6.9 K7.3 K113.6 K
Slightly volatile
Common StockM2.1 M14.2 M
Very volatile
Non Current Liabilities Total189 K198.9 K636.3 K
Very volatile
Net Receivables14.7 K15.5 K379.4 K
Slightly volatile
Other Assets66 K48.9 K146.5 K
Slightly volatile
Capital Surpluse297.8 M329.3 M277.7 M
Slightly volatile
Property Plant Equipment275.1 K458.5 K222.7 K
Slightly volatile
Net Invested Capital11.3 M9.7 M8.4 M
Slightly volatile
Net Working Capital2.6 M2.7 M7.8 M
Pretty Stable
Capital Stock1.6 M1.7 M23.6 M
Slightly volatile

Addex Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization247.1 K260.1 K662.1 K
Slightly volatile
Total Revenue383.9 K404.1 K1.7 M
Very volatile
Other Operating ExpensesM3.2 M13.2 M
Slightly volatile
Research Development811.6 K854.3 K5.3 M
Pretty Stable
Total Operating Expenses2.2 M2.3 M10.9 M
Pretty Stable
Selling General Administrative1.6 M1.7 MM
Slightly volatile
Interest Income8.7 K9.2 K92.4 K
Slightly volatile
Reconciled Depreciation270.5 K260.1 K146.6 K
Slightly volatile
Selling And Marketing Expenses1.8 MM2.2 M
Slightly volatile

Addex Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation1.2 M2.1 M1.2 M
Slightly volatile
Begin Period Cash Flow3.7 M3.9 M17.2 M
Slightly volatile
Depreciation247.1 K260.1 K662.1 K
Slightly volatile
End Period Cash Flow3.2 M3.3 M14.6 M
Slightly volatile
Issuance Of Capital Stock228.9 K240.9 K24 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.013.6865216
Slightly volatile
PTB Ratio0.550.580311.3826
Pretty Stable
Days Sales Outstanding13.1213.8089818
Slightly volatile
Book Value Per Share0.09360.09861.641
Slightly volatile
Average Payables1.4 M1.4 M1.1 M
Slightly volatile
Stock Based Compensation To Revenue3.172.983.106
Pretty Stable
Capex To Depreciation0.00460.00490.3504
Very volatile
PB Ratio0.550.580311.3826
Pretty Stable
Payables Turnover1.541.61894.7012
Pretty Stable
Sales General And Administrative To Revenue5.355.635922.1672
Slightly volatile
Average Inventory62.3 K73.3 K74.9 K
Very volatile
Research And Ddevelopement To Revenue1.381.450712.8322
Slightly volatile
Capex To Revenue0.00290.00310.3451
Slightly volatile
Cash Per Share0.03240.03411.6719
Slightly volatile
Days Payables Outstanding2142252.1 K
Pretty Stable
Intangibles To Total Assets0.00230.0030.0034
Pretty Stable
Net Debt To EBITDA0.670.71032.6316
Very volatile
Current Ratio6.334.40714.787
Very volatile
Tangible Book Value Per Share0.09360.09861.6377
Slightly volatile
Receivables Turnover27.7526.432211.7915
Slightly volatile
Graham Number0.320.360.3919
Slightly volatile
Shareholders Equity Per Share0.09360.09861.641
Slightly volatile
Debt To Equity0.00410.00430.0406
Slightly volatile
Capex Per Share0.00.00.0127
Slightly volatile
Graham Net Net0.02280.0241.3774
Slightly volatile
Average Receivables91.1 K95.9 K300.1 K
Slightly volatile
Revenue Per Share0.0040.00420.1726
Slightly volatile
Interest Debt Per Share4.0E-45.0E-40.0148
Slightly volatile
Debt To Assets0.00370.00390.0206
Slightly volatile
Price Book Value Ratio0.550.580311.3826
Pretty Stable
Days Of Payables Outstanding2142252.1 K
Pretty Stable
Ebt Per Ebit1.871.78181.123
Slightly volatile
Company Equity Multiplier1.51.10352.0318
Very volatile
Total Debt To Capitalization0.00410.00430.0355
Slightly volatile
Debt Equity Ratio0.00410.00430.0406
Slightly volatile
Quick Ratio6.334.40714.7843
Very volatile
Cash Ratio6.054.16634.5403
Very volatile
Days Of Sales Outstanding13.1213.8089818
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.00021.0125
Slightly volatile
Price To Book Ratio0.550.580311.3826
Pretty Stable
Fixed Asset Turnover9.129.600857.0493
Very volatile
Debt Ratio0.00370.00390.0206
Slightly volatile
Price Sales Ratio13.013.6865216
Slightly volatile
Asset Turnover0.07450.03840.0978
Slightly volatile
Price Fair Value0.550.580311.3826
Pretty Stable

Addex Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap5.3 M5.6 M41.2 M
Slightly volatile

Addex Fundamental Market Drivers

Cash And Short Term Investments3.3 M

Addex Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Addex Therapeutics Financial Statements

Addex Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Addex Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue270.2 K412.9 K
Total Revenue404.1 K383.9 K
Cost Of Revenue854.3 K811.6 K
Stock Based Compensation To Revenue 2.98  3.17 
Sales General And Administrative To Revenue 5.64  5.35 
Research And Ddevelopement To Revenue 1.45  1.38 
Ebit Per Revenue(6.72)(7.06)

Pair Trading with Addex Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Addex Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Addex Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Addex Stock

  0.77PFE Pfizer IncPairCorr
The ability to find closely correlated positions to Addex Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Addex Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Addex Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Addex Therapeutics to buy it.
The correlation of Addex Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Addex Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Addex Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Addex Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Addex Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Addex Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Addex Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Addex Therapeutics Stock:
Check out the analysis of Addex Therapeutics Correlation against competitors.
To learn how to invest in Addex Stock, please use our How to Invest in Addex Therapeutics guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Addex Therapeutics. If investors know Addex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Addex Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.52)
Revenue Per Share
0.36
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.25)
Return On Equity
(1.63)
The market value of Addex Therapeutics is measured differently than its book value, which is the value of Addex that is recorded on the company's balance sheet. Investors also form their own opinion of Addex Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Addex Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Addex Therapeutics' market value can be influenced by many factors that don't directly affect Addex Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Addex Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Addex Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Addex Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.